Project area or title
Predicting the risk of cardiometabolic impairments with antipsychotics: an individualised precision medicine approach
The average life expectancy of patients with psychosis is 15-20 years less than general population, with increased risk of cardiometabolic diseases being a major contributor to this. Antipsychotic medications, the mainstay treatment of psychosis, are known to increase risk of cardiometabolic illnesses, however, this risk varies greatly across different medications and for the same medication across individuals.
This PhD project will build on our ongoing work to predict the risk of cardiometabolic impairments with antipsychotics in an individual patient through alterations in mitochondrial metabolism to allow selection of the optimum treatment strategies thereby minimizing these impairments and their long term consequences.
Severe Mental Health
University of Nottingham